Previous Close | 1.6 |
1-Year Change | -78.92% |
6-Months Change | -20.79% |
3-Months Change | 0% |
Moving Avg (50d) | 1.9161 |
Moving Avg (200d) | 2.4722 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 438.1M |
Beta (3-Years) | 2.72 |
Revenue Growth (ttm) | -55.42% |
Net Profit Margin (ttm) | -521.65% |
Return On Assets (ttm) | -27.19% |
EPS (ttm) | -1.46 |
PE Ratio (ttm) | -1.1 |
Dividend Yield | % |
Asset Description: | Pacific Biosciences of California, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
1.764 | 1.71 | 1.674 | 1.62 | 1.53 | 1.44 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |